IFP Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $507K | Buy |
3,008
+216
| +8% | +$32K | 0.01% | 1033 |
|
|
2026
Q1 | $368K | Sell |
2,792
-89
| -3% | -$11.8K | 0.01% | 1098 |
|
|
2025
Q4 | $409K | Buy |
2,881
+406
| +16% | +$58.8K | 0.01% | 1016 |
|
|
2025
Q3 | $347K | Buy |
2,475
+303
| +14% | +$41.1K | 0.01% | 1015 |
|
|
2025
Q2 | $273K | Buy |
2,172
+88
| +4% | +$10.1K | 0.01% | 1109 |
|
|
2025
Q1 | $230K | Buy |
2,084
+64
| +3% | +$8.11K | 0.01% | 1110 |
|
|
2024
Q4 | $276K | Buy |
2,020
+137
| +7% | +$16.9K | 0.01% | 982 |
|
|
2024
Q3 | $217K | Sell |
1,883
-184
| -9% | -$25.2K | 0.01% | 1050 |
|
|
2024
Q2 | $285K | Sell |
2,067
-440
| -18% | -$60.3K | 0.01% | 862 |
|
|
2024
Q1 | $346K | Buy |
2,507
+455
| +22% | +$62.1K | 0.02% | 741 |
|
|
2023
Q4 | $270K | Buy |
2,052
+241
| +13% | +$27.7K | 0.01% | 826 |
|
|
2023
Q3 | $204K | Buy |
1,811
+16
| +0.9% | +$1.69K | 0.01% | 953 |
|
|
2023
Q2 | $169K | Sell |
1,795
-62
| -3% | -$6.06K | 0.01% | 1105 |
|
|
2023
Q1 | $183K | Sell |
1,857
-89
| -5% | -$9.26K | 0.01% | 979 |
|
|
2022
Q4 | $196K | Sell |
1,946
-339
| -15% | -$39.7K | 0.01% | 1364 |
|
|
2022
Q3 | $229K | Buy |
2,285
+567
| +33% | +$57.5K | 0.01% | 1332 |
|
|
2022
Q2 | $170K | Hold |
1,718
| – | – | 0.01% | 1369 |
|
|
2022
Q1 | $170K | Buy |
1,718
+235
| +16% | +$19.9K | 0.01% | 1369 |
|
|
2021
Q4 | $128K | Buy |
1,483
+12
| +0.8% | +$1.1K | ﹤0.01% | 1160 |
|
|
2021
Q3 | $141K | Sell |
1,471
-43
| -3% | -$4.06K | ﹤0.01% | 1130 |
|
|
2021
Q2 | $147K | Sell |
1,514
-111
| -7% | -$10.6K | ﹤0.01% | 1059 |
|
|
2021
Q1 | $158K | Buy |
1,625
+195
| +14% | +$20.4K | ﹤0.01% | 946 |
|
|
2020
Q4 | $137K | Buy |
1,430
+420
| +42% | +$40.6K | 0.01% | 978 |
|
|
2020
Q3 | $96K | Buy |
1,010
+890
| +742% | +$103K | 0.01% | 1018 |
|
|
2020
Q2 | $15K | Buy |
120
+10
| +9% | +$1.1K | ﹤0.01% | 1672 |
|
|
2020
Q1 | $10K | Sell |
110
-23
| -17% | -$2.25K | ﹤0.01% | 1777 |
|
|
2019
Q4 | $14K | Sell |
133
-77
| -37% | -$8.06K | ﹤0.01% | 1776 |
|
|
2019
Q3 | $19K | Buy |
+210
| New | +$19.6K | ﹤0.01% | 1787 |
|
|
2019
Q1 | $10K | Sell |
110
-207
| -65% | -$17.3K | ﹤0.01% | 1605 |
|
|
2018
Q4 | $22K | Sell |
317
-112
| -26% | -$10.7K | ﹤0.01% | 2078 |
|
|
2018
Q3 | $53K | Buy |
429
+112
| +35% | +$12.7K | ﹤0.01% | 1865 |
|
|
2018
Q2 | $31K | Buy |
317
+107
| +51% | +$9.58K | ﹤0.01% | 2207 |
|
|
2018
Q1 | $16K | Hold |
210
| – | – | ﹤0.01% | 2529 |
|
|
2017
Q4 | $16K | Buy |
210
+110
| +110% | +$7.5K | ﹤0.01% | 2565 |
|
|
2017
Q3 | $6K | Hold |
100
| – | – | ﹤0.01% | 3315 |
|
|
2017
Q2 | $5K | Hold |
100
| – | – | ﹤0.01% | 3415 |
|
|
2017
Q1 | $4K | Hold |
100
| – | – | ﹤0.01% | 3425 |
|
|
2016
Q4 | $4K | Sell |
100
-8
| -7% | -$362 | ﹤0.01% | 3410 |
|
|
2016
Q3 | $5K | Buy |
108
+8
| +8% | +$398 | ﹤0.01% | 3245 |
|
|
2016
Q2 | $5K | Sell |
100
-10
| -9% | -$460 | ﹤0.01% | 3155 |
|
|
2016
Q1 | $10K | Sell |
110
-29
| -21% | -$1.15K | ﹤0.01% | 1603 |
|
|
2015
Q4 | $8K | Buy |
+139
| New | +$7.07K | ﹤0.01% | 2698 |
|
Other funds holding NBIX
IFP Advisors's NBIX Position: Q2 2026 in Review
IFP Advisors increased its Neurocrine Biosciences (NBIX) stake by 7.7% in Q2 2026, buying an estimated $32K and bringing the position to 3,008 shares worth $507K. The position accounts for 0.01% of the portfolio, ranked #1033.
IFP Advisors first reported a position in NBIX in Q4 2015 and has held it in 42 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- IFP Advisors held 3,008 shares of Neurocrine Biosciences worth $507K as of Q2 2026.
- IFP Advisors bought 216 Neurocrine Biosciences shares in Q2 2026, an estimated $32K.
- Neurocrine Biosciences made up 0.01% of IFP Advisors's portfolio in Q2 2026, its #1033 holding.
- IFP Advisors first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 42 quarters since.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.